JP2013500314A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013500314A5 JP2013500314A5 JP2012522195A JP2012522195A JP2013500314A5 JP 2013500314 A5 JP2013500314 A5 JP 2013500314A5 JP 2012522195 A JP2012522195 A JP 2012522195A JP 2012522195 A JP2012522195 A JP 2012522195A JP 2013500314 A5 JP2013500314 A5 JP 2013500314A5
- Authority
- JP
- Japan
- Prior art keywords
- aryl
- heteroaryl
- alkyl
- ethyl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 12
- 125000003118 aryl group Chemical group 0.000 claims 9
- -1 2- (4-fluorophenyl) ethyl Chemical group 0.000 claims 8
- 125000001072 heteroaryl group Chemical group 0.000 claims 8
- 101100439663 Arabidopsis thaliana CHR7 gene Proteins 0.000 claims 4
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 230000006907 apoptotic process Effects 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 230000003013 cytotoxicity Effects 0.000 claims 2
- 231100000135 cytotoxicity Toxicity 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 230000001575 pathological effect Effects 0.000 claims 2
- 230000004962 physiological condition Effects 0.000 claims 2
- 238000004321 preservation Methods 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010011903 Deafness traumatic Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 101100134922 Gallus gallus COR5 gene Proteins 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010029155 Nephropathy toxic Diseases 0.000 claims 1
- 208000002946 Noise-Induced Hearing Loss Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 230000003796 beauty Effects 0.000 claims 1
- 239000003181 biological factor Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 230000007954 hypoxia Effects 0.000 claims 1
- 230000007813 immunodeficiency Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 210000004153 islets of langerhan Anatomy 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 230000007694 nephrotoxicity Effects 0.000 claims 1
- 231100000417 nephrotoxicity Toxicity 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ESP200901757 | 2009-07-30 | ||
| ES200901757 | 2009-07-30 | ||
| PCT/ES2010/000349 WO2011012746A2 (es) | 2009-07-30 | 2010-07-29 | Compuestos inhibidores de apaf-1 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013500314A JP2013500314A (ja) | 2013-01-07 |
| JP2013500314A5 true JP2013500314A5 (cg-RX-API-DMAC10.html) | 2013-09-12 |
| JP5694320B2 JP5694320B2 (ja) | 2015-04-01 |
Family
ID=43529761
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012522195A Expired - Fee Related JP5694320B2 (ja) | 2009-07-30 | 2010-07-29 | Ａｐａｆ−１阻害剤化合物 |
Country Status (15)
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006138380A2 (en) | 2005-06-15 | 2006-12-28 | Massachusetts Institute Of Technology | Amine-containing lipids and uses thereof |
| AU2009311667B2 (en) | 2008-11-07 | 2016-04-14 | Massachusetts Institute Of Technology | Aminoalcohol lipidoids and uses thereof |
| EP3318248B1 (en) | 2009-12-01 | 2019-04-10 | Translate Bio, Inc. | Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases |
| EP2609135A4 (en) | 2010-08-26 | 2015-05-20 | Massachusetts Inst Technology | POLY (BETA AMINO ALCOHOLS), THEIR PREPARATION AND USES THEREOF |
| US9238716B2 (en) | 2011-03-28 | 2016-01-19 | Massachusetts Institute Of Technology | Conjugated lipomers and uses thereof |
| BR112013031553A2 (pt) | 2011-06-08 | 2020-11-10 | Shire Human Genetic Therapies, Inc. | composições, mrna que codifica para uma hgla e seu uso, uso de pelo menos uma molécula de mrna e um veículo de transferência e uso de um mrna que codifica para proteína exógena |
| CN113149869A (zh) * | 2011-10-27 | 2021-07-23 | 麻省理工学院 | 能够形成药物包封微球的在n末端上官能化的氨基酸衍生物 |
| WO2013078413A1 (en) * | 2011-11-22 | 2013-05-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Modulators of lipid storage |
| EP3536787A1 (en) | 2012-06-08 | 2019-09-11 | Translate Bio, Inc. | Nuclease resistant polynucleotides and uses thereof |
| ES2443538B1 (es) * | 2012-07-19 | 2014-11-26 | Consejo Superior De Investigaciones Cientificas (Csic) | Compuestos beta-lactámicos inhibidores de APAF1 |
| CA2884870C (en) | 2012-08-13 | 2022-03-29 | Massachusetts Institute Of Technology | Amine-containing lipidoids and uses thereof |
| WO2014152966A1 (en) | 2013-03-14 | 2014-09-25 | Shire Human Genetic Therapies, Inc. | Methods for purification of messenger rna |
| KR102248744B1 (ko) | 2013-03-14 | 2021-05-06 | 샤이어 휴먼 지네틱 테라피즈 인크. | Cftr mrna 조성물 및 관련 방법 및 사용 |
| US9315472B2 (en) | 2013-05-01 | 2016-04-19 | Massachusetts Institute Of Technology | 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof |
| WO2015061467A1 (en) | 2013-10-22 | 2015-04-30 | Shire Human Genetic Therapies, Inc. | Lipid formulations for delivery of messenger rna |
| JP6506749B2 (ja) | 2013-10-22 | 2019-04-24 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | フェニルケトン尿症のためのｍＲＮＡ療法 |
| MX381303B (es) | 2013-10-22 | 2025-03-12 | Shire Human Genetic Therapies | Composición que comprende un ácido ribonucleico mensajero que codifica argininosuccinato sintetasa para usarse en el tratamiento de la deficiencia de argininosuccinato sintetasa. |
| KR20250005450A (ko) | 2014-04-25 | 2025-01-09 | 샤이어 휴먼 지네틱 테라피즈 인크. | 메신저 rna 의 정제 방법 |
| CA2949106C (en) | 2014-05-30 | 2023-10-24 | Shire Human Genetic Therapies, Inc. | Biodegradable lipids for delivery of nucleic acids |
| KR102387898B1 (ko) | 2014-06-24 | 2022-04-15 | 샤이어 휴먼 지네틱 테라피즈 인크. | 핵산의 전달용 입체화학적으로 풍부한 조성물 |
| WO2016004202A1 (en) | 2014-07-02 | 2016-01-07 | Massachusetts Institute Of Technology | Polyamine-fatty acid derived lipidoids and uses thereof |
| HUE062274T2 (hu) | 2015-06-19 | 2023-10-28 | Massachusetts Inst Technology | Alkenil-szubsztituált 2,5-piperazindionok és alkalmazásuk hatóanyag alanyba vagy sejtbe történõ célbajuttatására szolgáló készítményekben |
| EA201991747A1 (ru) | 2017-02-27 | 2020-06-04 | Транслейт Био, Инк. | НОВАЯ КОДОН-ОПТИМИЗИРОВАННАЯ мРНК CFTR |
| EP3624824B1 (en) | 2017-05-16 | 2024-07-10 | Translate Bio, Inc. | Codon-optimized mrna encoding cftr for use in treating cystic fibrosis |
| AU2019256527B2 (en) | 2018-04-19 | 2025-01-23 | Spiral Therapeutics, Inc. | Inner ear drug delivery devices and methods of use |
| WO2020041793A1 (en) | 2018-08-24 | 2020-02-27 | Translate Bio, Inc. | Methods for purification of messenger rna |
| WO2020106946A1 (en) | 2018-11-21 | 2020-05-28 | Translate Bio, Inc. | TREATMENT OF CYSTIC FIBROSIS BY DELIVERY OF NEBULIZED mRNA ENCODING CFTR |
| US10561736B1 (en) | 2019-01-09 | 2020-02-18 | Spiral Therapeutics, Inc. | Apoptosis inhibitor formulations for prevention of hearing loss |
| CA3131378A1 (en) | 2019-02-25 | 2020-09-03 | Spiral Therapeutics Inc. | Intratympanic injector devices and needles for delivery of drugs and methods of use |
| WO2021150890A2 (en) | 2020-01-24 | 2021-07-29 | Spiral Therapeutics Inc. | Devices, systems, and methods for treating ear disorders |
| EP4137131A1 (en) * | 2021-08-17 | 2023-02-22 | Centre National de la Recherche Scientifique (CNRS) | Novel serotonin analogues and their uses for treating iron-associated disorders |
| CN115124449B (zh) * | 2022-05-24 | 2024-02-02 | 上海英诺富成生物科技有限公司 | 一种吲哚化合物及制备方法与应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3560503A (en) * | 1968-09-18 | 1971-02-02 | Council Scient Ind Res | Di-lower alkyl-substituted octahydropyrazinopyrimidinones |
| GB1284582A (en) | 1969-11-10 | 1972-08-09 | Council Scient Ind Res | Substituted piperazinopyrimidinones |
| JPH04234375A (ja) | 1990-12-27 | 1992-08-24 | Ajinomoto Co Inc | 新規２，５−ジオキソピペラジン化合物及びその製造法 |
| FI934894A7 (fi) * | 1991-05-07 | 1993-11-05 | Merck & Co Inc | Fibrinogeenireseptorin antagonisteja |
| JPH05117246A (ja) | 1991-10-23 | 1993-05-14 | Ajinomoto Co Inc | 新規２，５−ジオキソピペラジン化合物とその製造法及びα−Ｌ−アスパルチル−Ｌ−フエニルアラニンメチルエステル誘導体の製造法 |
| WO1996000391A1 (en) * | 1994-06-23 | 1996-01-04 | Affymax Technologies N.V. | Methods for the synthesis of diketopiperazines |
| DE60201415T2 (de) * | 2001-01-19 | 2006-02-09 | Pharmacopeia, Inc. | Bisarylderivate mit fsh rezeptor modulierender aktivität |
| JP4674317B2 (ja) | 2002-10-02 | 2011-04-20 | ディエムアイ アクイジション コーポレイション | 疾病の判定および監視 |
| US20070128687A1 (en) * | 2003-11-28 | 2007-06-07 | Hajime Ikeda | Process for producing dipeptides |
| ES2296484B1 (es) * | 2005-11-23 | 2009-04-01 | Fundacion De La Comunidad Valenciana Centro De Investigacion Principe Felipe (90%) | Composicion farmaceutica para inhibir la apoptosis. |
| ES2293834B1 (es) * | 2006-07-20 | 2009-02-16 | Consejo Superior Investig. Cientificas | Compuesto con actividad inhibidora de las interacciones ubc13-uev, composiciones farmaceuticas que lo comprenden y sus aplicaciones terapeuticas. |
-
2010
- 2010-07-29 NZ NZ598125A patent/NZ598125A/en not_active IP Right Cessation
- 2010-07-29 IN IN1378DEN2012 patent/IN2012DN01378A/en unknown
- 2010-07-29 WO PCT/ES2010/000349 patent/WO2011012746A2/es not_active Ceased
- 2010-07-29 EP EP10803937.1A patent/EP2460798B1/en active Active
- 2010-07-29 BR BR112012002134A patent/BR112012002134B8/pt not_active IP Right Cessation
- 2010-07-29 EA EA201270215A patent/EA021838B1/ru not_active IP Right Cessation
- 2010-07-29 AU AU2010277505A patent/AU2010277505B2/en not_active Ceased
- 2010-07-29 ES ES10803937T patent/ES2727711T3/es active Active
- 2010-07-29 KR KR1020127005131A patent/KR101786761B1/ko not_active Expired - Fee Related
- 2010-07-29 JP JP2012522195A patent/JP5694320B2/ja not_active Expired - Fee Related
- 2010-07-29 CN CN201080043254.1A patent/CN102574818B/zh not_active Expired - Fee Related
- 2010-07-29 MX MX2012001339A patent/MX2012001339A/es active IP Right Grant
- 2010-07-29 CA CA2769408A patent/CA2769408C/en active Active
- 2010-07-29 TR TR2019/07804T patent/TR201907804T4/tr unknown
- 2010-07-29 US US13/387,240 patent/US9040701B2/en active Active